AII antagonists (candesartan and irbesartan) in the treatment of cardiovascular diseases

Czech version

Authors: J. Špinar ^1,3; J. Vítovec ^2,3
Authors‘ workplace: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ²; ICRC Brno, vedoucí programu doc. MUDr. Petr Němec, CSc., MBA ³
Published in: Vnitř Lék 2012; 58(10): 755-760
Category: Reviews

Overview

reatment of hypertension with angiotensin II receptor antagonists (AIIA) was first limited to diabetics and patients with microalbuminuria. So far, results of several large clinical trials with AIIAs were published, confirming significant renoprotective effect of these agents compared to placebo (RENAAL and IRMA), amlodipin (MARVAL and IDNT) and a combination of ACEI and AIIA (CALM). In 2002, results of 2 large comparator studies in hypertension were published: LIFE – Losartan Intervention For Endpoints and SCOPE – the Study on COgnition and Prognosis in Elderly hypertensives. In 2003, a series of the CHARM studies involving patients with heart failure were published and, from than, AIIA have been used as an alternative to ACEI or in a combination with ACEI. MOSES study – Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention – results were published in 2005 and ONTARGET study, focusing on secondary prevention of ischemic heart disease, was published in 2008. The CORD study – Comparison of recommended doses – and the ACTIVE I study (AF Clopidogrel Trial with Irbesartan for prevention of Vascular Events) were published in 2009. Candesartan was used in the CALM, SCOPE, RESOLVED and CHARM studies, irbesartan in the IRMA, IDNT and ACTIVE I.

Key words:
AII antagonists – candesartan – irbesartan – hypertension – heart failure – atrial fibrilation

Sources

1. American Diabetes Association. Diabetic Nefropathy. Diabetes Care 2002; 25 (Suppl 1): S85–S89.

2. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

3. Dahlöf B, Devereux RB, Kjeldsen SE. LIFE Study Group. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

4. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.

5. Hansson L, Lithell H, Skoog I et al. Study on cognition and prognosis in elderly hypertensives (SCOPE). Blood Press 1999; 8: 177–183.

6. 1999 World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151–183.

7. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

8. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–1064.

9. McMurray JJV, Östergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–771.

10. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–1444.

11. Muirhead N, Feagan BF, Mahon J et al. The effects of valsartan and captopril on reducing microalbuminuria in patiens with type 2 diabetes mellitus: a placebo-controlled Trial. Curr Ther Res 1999; 60: 650–660.

12. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.

13. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.

14. Schrader J, Lüders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–1226.

15. Špinar J, Lábrová R. ACTIVE I a upstream terapie. Interv Akut Kardiol 2009; 8: 325–327.

16. Špinar J, Vítovec J, Souček M et al. CORD investigators. Comparison of recommended doses of ACE inhibitors and angiotensin II receptor blockers. Vnitř Lék 2009; 55: 481–488.

17. Spinar J, Vitovec J, Soucek M et al. CORD Investigators. CORD: Comparison of recommended doses of ace inhibitors and angiotensin II receptor blockers. Int J Cardiol 2010; 144: 293–294.

18. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2007; 25: 1105–1187.

19. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

20. Vítovec J, Špinar J. Framakoterapie kardiovaskulárních onemocnění. Praha: Grada 2004.

21. Widimský J Jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101–118.

22. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection function: the CHARM-Preserved Trial. Lancet 2003; 362: 777–781.